Top news of the week: 02.06.2020.
Antibody, Hong Kong, Teochew people, Allergy, Gulf War, Health care
Startups
Jacobio will work on early global clinical trials of the two leading candidates out of its SHP2 portfolio, namely JAB-3068 and JAB-3312, but now AbbVie will start covering R&D expenses. https://t.co/qzjRB8LhEm
OpenAbbVie pens cancer pact with U.S.-China biotech Jacobio
AbbVie has signed a new pact to focus on SHP2 inhibitors, which target a key node in cancer and immune cells, from early-stage biotech Jacobio Pharmaceuticals.
This year's Next Billion-Dollar Startups list reflects the bright spots in a tough economy, notably healthcare https://t.co/rLpoMLfWEf by @amyfeldman https://t.co/MdYLaAWfWr
OpenNext Billion-Dollar Startups: Online Pharmacy Capsule Leads Healthcare- And Tech-Heavy List
This year's Next Billion-Dollar Startups list reflects the bright spots in a tough economy, notably healthcare.
Biotech R&D software startup Benchling, started by MIT undergrads, has scored a $850 million valuation amid the coronavirus pandemic https://t.co/NpcX69EQPv by @amyfeldman https://t.co/7Vxaesqzmw
OpenBiotech R&D Software Startup Benchling, Started By MIT Undergrads, Scores $850 Million Valuation Amid Coronavirus Pandemic
Forbes Under 30 alum Sajith Wickramasekara scores an $850 million valuation for his biotech R&D startup Benchling. Amid the coronavirus pandemic, the company is helping big biotech ...
AbCellera, the biotech company partnering with major pharmaceutical players like Lilly on Covid-19 drug development, has raised $105 million in funding to ramp up https://t.co/R5cLoIvwy5 by @TheAlexKnapp https://t.co/UBPR6U3PFY
OpenAbCellera Raises $105 Million To Boost Drug Discovery Against Coronavirus And Other Diseases
The Vancouver-based biotech firm aims to nearly double its head count and expand its R&D efforts to find antibodies to treat disease.
Also, the story of how AbCellera and $LLY started this drug is pretty interesting. Details:
https://t.co/qS5uZnZ2kp
OpenEli Lilly begins first human tests of an antibody drug against Covid-19
The medicine, a human-made antibody against the coronavirus that causes the disease, was discovered by a Vancouver company.
The headline part of the deal sees Gilead join companies including Merck and Roche in the race to bring an anti-TIGIT antibody to market, which could be the future of immuno-oncology. https://t.co/FLWKADCHtW
OpenGilead pens $2B Arcus pact for immuno-oncology targets of the past and future
Last month, rumors out of Bloomberg whispered that Gilead Sciences, more known for its COVID-19 work these days, was gearing up for a major stake in immuno-oncology player Arcus.
RT @BursatilBiotech: Absolutely no words to describe this article other than truly wonderful & thoughtful piece from @nbhorwitz.
Pandemic is awful. Context is tragic worldwide and yet, we cant help being selfish.
It's a must read. Believe me.
https://t.co/0ygJyyBZ3E https://t.co/9DhWHVURSQ
Open
From @Breakingviews: UBI Banca makes a strange attempt to escape Intesa Sanpaolo’s hostile bid, and Hong Kong investors get biotech fever. Catch up with the latest financial insights here https://t.co/hk94AEQGDs
OpenBreakingviews - Corona Capital: Safe offices, MAC hack, HK biotech
(Reuters Breakingviews) - Corona Capital is a daily column updated throughout the day by Breakingviews columnists around the world with short, sharp pandemic-related insights.